purine has been researched along with Leukemia, Hairy Cell in 4 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
Leukemia, Hairy Cell: A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 8.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
| "Hairy cell leukemia (HCL) is a B-cell malignancy that in its classic form is exquisitely sensitive to single-agent purine analog therapy, but that is associated in many patients with late relapse and eventual purine analog resistance." | 4.88 | Immunoconjugates and new molecular targets in hairy cell leukemia. ( Kreitman, RJ, 2012) |
| "Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 4.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
| "Although hairy cell leukemia (HCL) was identified in 1958 by Bouroncle and colleagues, HCL remains in 2015 a mysterious disease." | 2.52 | New insights in the management of patients with hairy cell leukemia. ( Cornet, E; Damaj, G; Troussard, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, R | 1 |
| Wei, W | 1 |
| Mian, A | 1 |
| Gonter-Aubin, K | 1 |
| Kabel, C | 1 |
| Mato, A | 1 |
| Stephens, DM | 1 |
| Hanlon, A | 1 |
| Khajavian, S | 1 |
| Shadman, M | 1 |
| Brander, D | 1 |
| Madanat, Y | 1 |
| Park, JH | 1 |
| Tallman, M | 1 |
| Pinilla-Ibarz, J | 1 |
| Hill, BT | 1 |
| Topp, ZZ | 1 |
| Saven, A | 1 |
| Cornet, E | 1 |
| Damaj, G | 1 |
| Troussard, X | 1 |
| Kreitman, RJ | 1 |
3 reviews available for purine and Leukemia, Hairy Cell
| Article | Year |
|---|---|
Hairy cell leukemia: a 'hair-raising' update.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow; Drug Therapy, Combination; Humans; Leuke | 2014 |
New insights in the management of patients with hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B-Lymphocytes; Disease-Free Survival; Humans; Immunot | 2015 |
Immunoconjugates and new molecular targets in hairy cell leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; B-Lymphocytes; Bacterial Toxins; Exotoxins; | 2012 |
1 other study available for purine and Leukemia, Hairy Cell
| Article | Year |
|---|---|
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Topics: Humans; Leukemia, Hairy Cell; Nucleosides; Purine Nucleosides; Purines; Recurrence; Rituximab; Treat | 2022 |